TMEM92 shields DDX3X from TTC3‐mediated degradation to confer chemoresistance in triple‐negative breast cancer
Clinical and Translational Medicine · 2026-05 · 16 (5)
DOI: 10.1002/ctm2.70681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 15.05.2026. Verfasst von Hao Shen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Breast Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, DEAD-box RNA Helicases, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission Scientific Research Project, The Seventh Cycle of Key Medical Specialties in Jinshan District-Ultrasound Department (Back-up Category), Three-Year Action Plan for Talent Team Construction (2023-2025) Implementation Plan of Jinshan Hospital Affiliated to Fudan University, there is a key developm….
Abstract (Originalsprache)
Background
Triple‐negative breast cancer (TNBC) remains a major clinical challenge because of its aggressive characteristics, limited targeted treatment options, and frequent chemoresistance. However, the molecular mechanisms governing protein stability that drive TNBC progression and therapeutic resistance remain incompletely understood.
Methods
TMEM92 expression and clinical relevance were evaluated using public datasets, patient specimens, and TNBC cell models. Loss‐of‐function, rescue, xenograft, protein interaction, and ubiquitination assays were performed to determine the biological function and molecular mechanism of TMEM92 in TNBC progression and cisplatin response.
Results
TMEM92 was prominently expressed in TNBC and correlated with poor prognosis. Functionally, depletion of TMEM92 suppressed TNBC cell proliferation, migration, invasion, and survival while promoting apoptosis in vitro and in vivo. Mechanistically, TMEM92 directly associated with DEAD‐box helicase 3 X‐linked (DDX3X) and protected it from degradation by the E3 ubiquitin ligase tetratricopeptide repeat domain 3 (TTC3). TMEM92 competitively prevented TTC3 binding to DDX3X, thereby inhibiting TTC3‐mediated K48‐linked ubiquitination and subsequent proteasomal degradation of DDX3X. Re‐expression of DDX3X rescued the anti‐tumor effects induced by TMEM92 knockdown. Therapeutically, TMEM92 targeting sensitized TNBC cells and xenograft tumors to cisplatin. TMEM92 knockout reduced the cisplatin IC 50 by 44.0% in MDA‐MB‐231 cells and 42.9% in BT‐549 cells, and TMEM92 depletion enhanced cisplatin‐induced tumor growth inhibition by approximately 70.6% compared with cisplatin alone.
Conclusions
This study identifies a novel TMEM92DDX3XTTC3 axis that regulates DDX3X protein stability and drives TNBC progression and chemoresistance, revealing a potential prognostic and therapeutic vulnerability in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid Breast Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Medical Ultrasound, Jinshan Hospital of Fudan University, Shanghai, China.
- Center of Hepatobiliary Pancreatic Disease, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
- Department of Breast and Thyroid Surgery, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Key Laboratory of Breast Cancer in Shanghai, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Förderung
- Shanghai Municipal Health Commission Scientific Research Project
- The Seventh Cycle of Key Medical Specialties in Jinshan District-Ultrasound Department (Back-up Category)
- Three-Year Action Plan for Talent Team Construction (2023-2025) Implementation Plan of Jinshan Hospital Affiliated to Fudan University, there is a key developm…
- Natural Science Research Program of Huai'an, Jiangsu, China
- Scientific Research Program of the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University
- The Wu Jieping Medical Foundation
Zitieren
APA
Shen, H., Jia, X., Li, X., Li, Z., Zhang, Z., Zhao, Y., Shen, L., Bu, X., Ma, Q., Liang, C., Lin, X., Ma, L. X., & Qin, C. (2026). TMEM92 shields DDX3X from TTC3‐mediated degradation to confer chemoresistance in triple‐negative breast cancer. Clinical and Translational Medicine, 16(5). https://doi.org/10.1002/ctm2.70681
Vancouver
Shen H, Jia X, Li X, Li Z, Zhang Z, Zhao Y, et al. TMEM92 shields DDX3X from TTC3‐mediated degradation to confer chemoresistance in triple‐negative breast cancer. Clinical and Translational Medicine. 2026;16(5). doi:10.1002/ctm2.70681
BibTeX
@article{Shen2026,
author = {Shen, Hao and Jia, Xiaochao and Li, Xu and Li, Zhi and Zhang, Zhihua and Zhao, Yang and Shen, Lei and Bu, Xiaoqiu and Ma, Qiang and Liang, Chunli and Lin, Xiaoti and Ma, Lin-Xiaoxi and Qin, Chuan},
title = {TMEM92 shields DDX3X from TTC3‐mediated degradation to confer chemoresistance in triple‐negative breast cancer},
journal = {Clinical and Translational Medicine},
year = {2026},
volume = {16},
number = {5},
doi = {10.1002/ctm2.70681}
}
EUVIMED